Envestnet Asset Management
RCUS icon

Envestnet Asset Management’s Arcus Biosciences RCUS Stock Holding History

Envestnet Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,495
Closed -$279K – 4081
2022
Q4 		$279K Buy
+13,495
New +$371K ﹤0.01% 3469

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Envestnet Asset Management's RCUS Position: Q1 2023 in Review

Envestnet Asset Management sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 13,495 shares — an estimated $279K sold.

Envestnet Asset Management first reported a position in RCUS in Q4 2022 and held it in 1 quarter. The position peaked at $279K in Q4 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • Envestnet Asset Management reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 13,495 Arcus Biosciences shares in Q1 2023, an estimated $279K.
  • Envestnet Asset Management first reported a position in Arcus Biosciences in Q4 2022 and held it in 1 quarter.
  • Envestnet Asset Management's Arcus Biosciences position peaked at $279K in Q4 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.